Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217940 · ClinicalTrials.gov registry record · NA
Screening Women With Prior HPV for Anal Neoplasia
A NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT05217940: Recruiting NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05217940 is a NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05217940, a NA study of HPV-related Lower Genital Tract Neoplasias and HPV-related Anal Neoplasias, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
Primary Outcome
Test sensitivity and specificity
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Diagnostic tests for anal cancer screening
Study Locations (3)
New York
- Icahn School of Medicine at Mount Sinai - New York
South Carolina
- Medical University of South Carolina - Charleston
Texas
- University of Texas M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2027-01 |
| Phase | NA |
What NCT05217940 shows while recruiting
NCT05217940 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with HPV-related Lower Genital Tract Neoplasias appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic tests for anal cancer screening is the first listed.
NCT05217940 reports a single indexed study location in New York, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT05217940 about?
NCT05217940 is a clinical study titled "Screening Women With Prior HPV for Anal Neoplasia". The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
What is the current status of trial NCT05217940?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2022-03-02. Estimated completion is 2027-01.
What conditions does trial NCT05217940 study?
This clinical trial studies the following conditions: HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers.
What interventions are being tested in trial NCT05217940?
The interventions under investigation include: Diagnostic tests for anal cancer screening (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05217940?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05217940 being conducted?
This trial has 3 study locations across New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05217940's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI